Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on sensitive biological samples.
The decision became public following a official document dated December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesperson has since explained that the US was seeking genetic material for research and profit while was not willing to guarantee the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for further negotiations to secure a deal suitable to both sides so the country's vital HIV programme can continue.
Broader Implications
Zimbabwe's decision follows a comparable case in Kenya, where a court blocked a similar deal with the US following concerns were raised about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
As per statements, 16 nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no corresponding promise of access to any medical innovations – such as new medicines or tests – that might result from that shared data," he stated.
"Put simply, our country would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our people if a new pandemic arise."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were upending frameworks already established through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future co-operation might be arranged in a way that honours the independence and dignity of both nations."
Health Experts Reaction
Medical experts expressed it understood the government's concerns, but suggested that negotiations must proceed considering a large portion of the country's HIV programmes depended on external financing.
"In cases where specific concerns arise, including those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the ongoing challenges between receiving vital international aid and protecting a country's data in an increasingly data-driven world.